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Ulcerative colitis and Crohnʼs disease are chronic inflammatory bowel diseases (IBD) of unknown 
etiology. In recent years, mucosal healing has emerged as the goal for therapy to achieve long-term 
remission and to change the natural course of IBD. Thus, it is essential to monitor thoroughly the 
disease activity. Fecal calprotectin is the best available biomarker of disease activity in IBD. 
The overall aim of this thesis was to study the clinical usefulness of fecal calprotectin. Four different 
patient cohorts were investigated.  
For patients with active ulcerative colitis, the fecal calprotectin levels varied considerably, even over a 
single day, and the variability was considered to be clinically important in up to one-third of the 
patients. However, the longer the time period between bowel movements, the higher were the 
concentrations of calprotectin. To reduce both the impact of the variability and the risk of false low 
calprotectin values, samples should be obtained from the first stool passed in the morning. In stool 
samples stored at room temperature, the concentrations of calprotectin were stable for 3 days, while 
the levels decreased significantly after 7 days. In a questionnaire, the patients with IBD declared that 
they did not find it burdensome to obtain stool samples, although suitable equipment was considered 
desirable. 
The levels of fecal calprotectin did not distinguish between patients with endoscopic recurrence 1 year 
after ileocaecal resection for Crohn’s disease and those without. However, in patients with low 
calprotectin values, endoscopic remission was commonly noted, suggesting that a colonoscopy might 
be avoided in these cases. 
In the group of patients with quiescent ulcerative colitis, dose escalation of 5-aminosalicylic acid (5-
ASA) in those patients identified with increased levels of calprotectin significantly reduced the relapse 
rate. However, the overall relapse rate of the intervention group was not significantly lower than that 
of the control group. 
At cut-off values for calprotectin of 169 µg/g and 262 µg/g, the clinical course in patients with newly 
diagnosed ulcerative colitis could be predicted with good specificity and moderate sensitivity, for 1 
and 3 years, respectively. 
Conclusions: These results facilitate standardization of the stool sampling procedure, which is 
necessary to improve the accuracy of this biomarker. Furthermore, fecal calprotectin might be used to 
select patients for ileocolonoscopy 1 year after ileocaecal resection for Crohnʼs disease. To treat 
patients with IBD in clinical remission, but with increased values of calprotectin suggesting 
subclinical disease activity, brings a new dimension to IBD care. In this context, dose escalation of 5-
ASA may be appropriate in patients with ulcerative colitis. This therapeutic concept should be tested 
also in patients with new onset of ulcerative colitis.  
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